Gsk Plc · LSE:GSK
Gsk — JP Morgan Conference 2016
14 slides from Gsk's conference presentation, Jan 12, 2016
Slide 1: GSK Sir Andrew Witty, CEO – JP Morgan Conference
GSK Sir Andrew Witty, CEO JP Morgan Conference 12 January 2016
Slide 2: Progress through 2015 positions GSK to respond to global changes and maximise opportunities
Progress through 2015 positions GSK to respond to global changes and maximise opportunities Global leadership positions underpin future growth 3 growth businesses ^ Balanced geographies^ - 2016 core EPS expected to reach double digit growth (CER)* - 2016 to 2020 outlook core EPS mid-to- high single
Slide 3: Significant growth from new products
Significant growth from new products New Pharma products** showing strong contribution New product growth* more than Q3 2015 sales offsets Advair decline 6.1% 5.6% 4.8% 4.4% 4.1% 14.0% 13.9% Q115 Q1 Q215 Q2 Q315 Q3 £412m New product £321m growth*^ £221m Seretide/ Advair £141m £135m £182m decline^ 86
Slide 4: Select key 2015 milestones
Select key 2015 milestones 3 part Novartis transaction completed in March Industry leading transformation of commercial operating model Integration and significant cost savings on track Key 11 new products on track to generate >£6bn annual sales by 2020* Substantial R&D progress on next wave of asse
Slide 5: Pharma 2015: new Respiratory products gaining scale
Pharma 2015: new Respiratory products gaining scale Breo Anoro and Incruse Significant improvement in US ICS/LABA Improving share of US LAMA market post new managed market share post asthma launch care coverage and Open Triple use in Q4 14% 30% 12% 25% Share of market Share of market 10% 20% 8% 15%
Slide 6: Pharma 2015: HIV growth acceleration
Pharma 2015: HIV growth acceleration Share of all dynamic patients vs competitor products (3rd Agent + STR) 35% Share of Naïve Patients 40% Total DTG 30% 29% 28.6% 25% 35% Total DTG 20% 33.4% 15% 30% 10% 26% 25% 5% 0% 20% 15% 45% Share of Switch Patients 40% Total DTG 35% 37.8% 10% 30% 25% 23.4% 5%
Slide 7: Pharma 2015: BMS transactions bolstering a leading pipeline with highly complementary assets
Pharma 2015: BMS transactions bolstering a leading pipeline with highly complementary assets Next generation*† agents with game changing potential Maturation Inhibitor*† w/ possible combinations with DTG and/or CAB Attachment Inhibitor* † f or highly Search for remission and cure experienced patient
Slide 8: Vaccines 2015: broad portfolio driving growth, realising benefits from integration
Vaccines 2015: broad portfolio driving growth, realising benefits from integration and ongoing investments New meningitis portfolio Shingrix 90-97% efficacy against Proactive supply 9M global sales +63%* shingles in two Phase III studies network upgrades 140 100 enabled accelerated 90 delivery sched
Slide 9: Consumer 2015: innovation and geographic position driving growth
Consumer 2015: innovation and geographic position driving growth, focus on accelerating integration 9M sales +7%, core operating Competitive global footprint with profit +19%* opportunities for expansion* US Flonase RxCx switch success 24% contributed >50% of US Q3 growth Int 47% EU 29% Integration
Slide 10: R&D strategy: focus on long term sustainable innovation
R&D strategy: focus on long term sustainable innovation Accelerate Focus where Balance of internal Reduce fixed cost science is Discovery output innovative vs external to drive ROI • Now have 30 DPUs, of which 2/3’s are • Of the ~40 assets profiled, • 60% of NMEs* in the clinic • Balance discovery a
Slide 11: Potential to file up to 20 assets by 2020
Potential to file up to 20 assets by 2020 2014 2018 2021 to to to 2017 2020 2025 7 NMEs & 5 PLEs 11 NMEs & 5 PLEs 21 NMEs & 5 PLEs Nucala sirukumab mepolizumab tarextumab† GSK2398852+ sirukumab GSK3008348 GSK525762 GSK3196165 RSV paediatric (mepolizumab) IL-6 mAb IL-5 mAb Notch 2/3 mAb GSK2315698 IL
Slide 12: Progress in Oncology
Progress in Oncology 2016/ 17 select key milestones Immuno-Oncology Epigenetics Stem Cells and Targeted Abs EZH2 PRMT5 OX-40 Inhibitor Inhibitor Agonist Notch 1 BET Antagonist PD1 RP2D 2016 FTIH Start Q216 Inhibitor combination Combo Phase start 2016 LSD1 study start Ib combo start Inhibitor & singl
Slide 13: 2016 return to growth
2016 return to growth Select key milestones Business R&D Financials performance • 2016 core EPS expected to reach • Anticipated completion of two • Restructuring on track, including double digit growth CER* BMS transactions material savings in 2016 • Continued strong contribution • Filing: Shingrix,
Slide 14: Cautionary statement regarding forward-looking statements
Cautionary statement regarding forward-looking statements This presentation may contain f orward-looking statements. Forward-looking statements give the Group’s current expectations or f orecasts of f uture events. An investor can identif y these statements by the f act that they do not relate stric